Evidence map›Paper›PMID 40849365›Full record

ArticleMikrochimica acta2025

Nucleus delivery of doxorubicin by gadolinium-functionalized carbon dot drug delivery system for HCC imaging and therapy.

Boyang Xue, Qiang Li, Yanjiao Xing, Hongkai Mu, Yongzhen Yang, Lin Chen, Shiping Yu, Rongrong Guo

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Boyang Xue *Key Laboratory of Interface Science and Engineering in Advanced Materials, Ministry of Education, Taiyuan University of Technology, Taiyuan, 030024, PR China.
Qiang Li *Interventional Therapy Department, Second Hospital of Shanxi Medical University, Taiyuan, 030001, PR China.
Yanjiao XingKey Laboratory of Interface Science and Engineering in Advanced Materials, Ministry of Education, Taiyuan University of Technology, Taiyuan, 030024, PR China.
Hongkai MuInterventional Therapy Department, Second Hospital of Shanxi Medical University, Taiyuan, 030001, PR China.
Yongzhen YangKey Laboratory of Interface Science and Engineering in Advanced Materials, Ministry of Education, Taiyuan University of Technology, Taiyuan, 030024, PR China. yangyongzhen@tyut.edu.cn.
Lin ChenKey Laboratory of Interface Science and Engineering in Advanced Materials, Ministry of Education, Taiyuan University of Technology, Taiyuan, 030024, PR China. chenlin01@tyut.edu.cn.
Shiping YuInterventional Therapy Department, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, PR China.
Rongrong GuoUltrasound Department, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, PR China. guorongrong2@sxmu.edu.cn.

Funding

Foundational Research Project of Shanxi Province 202203021211044Foundational Research Project of Shanxi Province 202203021211159Four "Batches" Innovation Project of Invigorating Medical through Science and Technology of Shanxi Province 2023XM012Key International Science and Technology Cooperation Projects of Shanxi Province 202304041101002National Natural Science Foundation of China 82172048Research Project of Health Commission of Shanxi Province 2023120Research Project of Second Hospital of Shanxi Medical University 202302-3Shanxi Center of Technology Innovation for Controlled and Sustained Release of Nano-drugs 202104010911026Shanxi Scholarship Council of China 2024-058The Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital TD2023003
6 · The paper itself

Abstract

To overcome the dual challenges of suboptimal therapeutic outcomes and delayed detection in hepatocellular carcinoma (HCC), a nucleus-targeting theranostic nanoplatform based on gadolinium-functionalized carbon dots (GdCDs) is presented. GdCDs were synthesized via a one-step hydrothermal method utilizing neutral red and citric acid as carbon precursors and gadolinium chloride hexahydrate as the paramagnetic source, showing good fluorescence (FL) and magnetic resonance imaging (MRI) capabilities. After modified with a nuclear localization sequence (NLS), GdCDs were loaded with doxorubicin (DOX) to yield the integrated theranostic platform: Nucleus-targeting gadolinium-functionalized carbon dot drug delivery system (NT-GdCDs-DDS) for FL/MRI dual-modality imaging and nucleus-targeting drug delivery. NT-GdCDs-DDS exhibited optimal excitation/emission wavelengths at 497/596 nm, a high longitudinal relaxivity (r

Indexed as

Antibiotics, AntineoplasticCarcinoma, HepatocellularDoxorubicinDrug CarriersDrug Delivery SystemsGadoliniumLiver NeoplasmsQuantum DotsAnimalsCarbonCell NucleusCell SurvivalHep G2 CellsHumansMagnetic Resonance ImagingMiceAntibiotics, AntineoplasticCarbonDoxorubicinDrug CarriersGadoliniumCarbon dotsFluorescence imagingMagnetic resonance imagingNucleus-targetingTheranostics

Identifiers

PMID40849365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.